Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 12 of 46

Clinical Questions Addressed by the CER (1 of 2)

Despite being widely used, there are still unanswered questions about the effectiveness and safety of DMARDs used to treat JIA, including:

  • What is the effectiveness of DMARDs when compared with conventional anti-inflammatory/anti-immune treatments?
  • What is the comparative effectiveness of DMARDs, both within a drug class and between drug classes?
  • What is the long-term safety of the DMARDs? Drugs in both categories carry safety warnings. Anti–TNF-α DMARDs are associated with increased risk of cancer (lymphoma) and serious infections.